Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Pancreatitis

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 64 articles: HTML format

Single Articles

May 2026
1. MIYAZAWA M, Takatori H, Nishitani M, Komura T, et al
   A decade of clinical course and prognostic determinants in type 1 autoimmune pancreatitis: insights from a 10-year longitudinal multicenter retrospective study.
   J Gastroenterol. 2026 May 25. doi: 10.1007/s00535-026-02448.
   PubMed     Abstract available
   
   
   
2. UMEMOTO K, Nakahara K, Ohike N, Satta Y, et al
   Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens.
   J Gastroenterol. 2026 May 23. doi: 10.1007/s00535-026-02447.
   PubMed     Abstract available
   
   
   
3. MASAMUNE A, Sano T, Takikawa T, Matsumoto R, et al
   Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021.
   J Gastroenterol. 2026 May 19. doi: 10.1007/s00535-026-02438.
   PubMed     Abstract available
   
   
   
4. XIAO J, Li W, Pan J, Yang Y, et al
   S-adenosylhomocysteine hydrolase-like protein 1 deficiency resulted in stronger inflammation reaction in acute pancreatitis.
   J Gastroenterol. 2026 May 9. doi: 10.1007/s00535-026-02437.
   PubMed     Abstract available
   
   
   
5. HASHIMOTO D, Ikeura T, Maekawa A, Nakajima T, et al
   Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study.
   J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02432.
   PubMed     Abstract available
   
   
   
6. OBA A, Taguchi T, Fujikawa N, Okami S, et al
   Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.
   J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02431.
   PubMed     Abstract available
   
   
   
7. FAGHIH M, Damm M, Gutzler C, Hirth M, et al
   Pathophysiology, assessment, and treatment of pain in patients with pancreatic ductal adenocarcinoma.
   J Gastroenterol. 2026 May 2. doi: 10.1007/s00535-026-02423.
   PubMed     Abstract available
   
   
   
8. HANAKI T
   Regional disparities in pancreaticoduodenectomy mortality: more than just rurality?
   J Gastroenterol. 2026 May 1. doi: 10.1007/s00535-026-02436.
   PubMed    
   
   
   April 2026
9. ISHIGAKI K, Nakai Y, Kashiwabara K, Fujishiro M, et al
   Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01).
   J Gastroenterol. 2026 Apr 17. doi: 10.1007/s00535-026-02413.
   PubMed     Abstract available
   
   
   
10. LEE Y, Oh D, Cho SH, Hong SM, et al
    Immune checkpoint inhibitor-related pancreatitis: a comprehensive review of epidemiology, pathophysiology, and management.
    J Gastroenterol. 2026 Apr 1. doi: 10.1007/s00535-026-02389.
    PubMed     Abstract available
    
    
    March 2026
11. KOYAMA K, Takahashi K, Ono Y, Oyama K, et al
    Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2026 Mar 10. doi: 10.1007/s00535-026-02382.
    PubMed     Abstract available
    
    
    
12. KOYAMA T, Nawa N, Nishimura H, Hanafusa M, et al
    Regional differences for the risk of in-hospital mortality after pancreaticoduodenectomy: a cross-sectional study analyzing data from a Japanese nationwide database including 86,339 patients.
    J Gastroenterol. 2026 Mar 2. doi: 10.1007/s00535-026-02357.
    PubMed     Abstract available
    
    
    February 2026
13. NISHIDA T, Sugimoto A, Matsumoto K
    Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients.
    J Gastroenterol. 2026 Feb 27. doi: 10.1007/s00535-026-02376.
    PubMed    
    
    
    
14. SHIMAMOTO N, Sumiyama K, Fujita Y
    Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02350.
    PubMed     Abstract available
    
    
    
15. YANG A, Pan C, Gu C, Luo B, et al
    YAP1-driven tumor-like cancer-associated fibroblasts modulate biomechanics of pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2026 Feb 3. doi: 10.1007/s00535-026-02346.
    PubMed     Abstract available
    
    
    
16. ROBATEL S, Hillen H, Mutisheva I, Muller JC, et al
    Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2026 Feb 1. doi: 10.1007/s00535-026-02347.
    PubMed     Abstract available
    
    
    January 2026
17. REN H, Fei H, Niu P, Xu X, et al
    An interpretable machine learning model for predicting survival in pancreatic cancer via SHAP: a multicenter study.
    J Gastroenterol. 2026 Jan 30. doi: 10.1007/s00535-026-02348.
    PubMed     Abstract available
    
    
    
18. UEMATSU Y, Matsuda S, Kitago M, Uemura S, et al
    Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2026 Jan 11. doi: 10.1007/s00535-026-02343.
    PubMed     Abstract available
    
    
    
19. IKEMOTO J, Ishii Y, Hanada K, Sasaki T, et al
    Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan.
    J Gastroenterol. 2026 Jan 3. doi: 10.1007/s00535-025-02340.
    PubMed     Abstract available
    
    
    November 2025
20. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Correction: Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Nov 26. doi: 10.1007/s00535-025-02329.
    PubMed    
    
    
    
21. MATSUMOTO R, Kikuta K, Takikawa T, Nakai Y, et al
    Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer.
    J Gastroenterol. 2025 Nov 18. doi: 10.1007/s00535-025-02321.
    PubMed     Abstract available
    
    
    
22. MASAMUNE A, Masson E, Zou WB, Rygiel AM, et al
    TRPV6-related pancreatitis: natural history and the impact of the pancreas-specific deletion on pancreatitis in mice.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02323.
    PubMed     Abstract available
    
    
    
23. HAYASHI N, Takahara T, Yasuda I, Kawanaka H, et al
    Development of novel serum peptide biomarkers for screening pancreatic cancer.
    J Gastroenterol. 2025 Nov 5. doi: 10.1007/s00535-025-02314.
    PubMed     Abstract available
    
    
    October 2025
24. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02303.
    PubMed     Abstract available
    
    
    September 2025
25. WANG X, Zhang Y, Li A, Zhou C, et al
    STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.
    J Gastroenterol. 2025 Sep 19. doi: 10.1007/s00535-025-02291.
    PubMed     Abstract available
    
    
    July 2025
26. TANAKA Y, Masamune A, Matsumoto R, Takikawa T, et al
    Nationwide epidemiological survey of acute pancreatitis in Japan, 2021: the impact of the COVID-19 pandemic and revised clinical guidelines.
    J Gastroenterol. 2025 Jul 31. doi: 10.1007/s00535-025-02284.
    PubMed     Abstract available
    
    
    
27. EMORI T, Itonaga M, Ashida R, Ishihara T, et al
    Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line gemcitabine and nab-paclitaxel: a prospective study.
    J Gastroenterol. 2025 Jul 17. doi: 10.1007/s00535-025-02283.
    PubMed     Abstract available
    
    
    June 2025
28. LIU S, Su J, Zhao H, Bai R, et al
    Correction: Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2025 Jun 27. doi: 10.1007/s00535-025-02274.
    PubMed    
    
    
    
29. LEI S, Zhang Z, Zeng Z, Cao W, et al
    aGenome-scale activation screen reveals lncRNA HNF1A-AS1 promotes pancreatic cancer metastasis through interacting with U2SURP to increase CD44 alternative splicing.
    J Gastroenterol. 2025 Jun 15. doi: 10.1007/s00535-025-02272.
    PubMed     Abstract available
    
    
    May 2025
30. NISHIWADA S, Nakamura K, Ozu N, Terai T, et al
    An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer.
    J Gastroenterol. 2025 May 10. doi: 10.1007/s00535-025-02260.
    PubMed     Abstract available
    
    
    
31. ENDO G, Ishigaki K, Nakai Y, Nishio H, et al
    Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02253.
    PubMed     Abstract available
    
    
    
32. MANAKA T, Takikawa T, Tarasawa K, Kikuta K, et al
    Current status and trends in ERCP and post-ERCP pancreatitis in Japan: a nationwide observational study.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02254.
    PubMed     Abstract available
    
    
    April 2025
33. LIU S, Su J, Zhao H, Bai R, et al
    Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2025 Apr 26. doi: 10.1007/s00535-025-02252.
    PubMed     Abstract available
    
    
    March 2025
34. WU Z, Yang J, Ma Z, Chen Y, et al
    Nuclear magnetic resonance-based metabolomics and risk of pancreatic cancer: a prospective analysis in the UK Biobank.
    J Gastroenterol. 2025 Mar 12. doi: 10.1007/s00535-025-02237.
    PubMed     Abstract available
    
    
    January 2025
35. ABU-SERIE MM, Gutierrez-Garcia AK, Enman M, Vaish U, et al
    Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancreatic cancer.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02213.
    PubMed     Abstract available
    
    
    
36. IMAOKA H, Ikeda M, Kobayashi S, Ohba A, et al
    Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
    J Gastroenterol. 2025 Jan 29. doi: 10.1007/s00535-025-02215.
    PubMed    
    
    
    
37. HU K, Zhao X, Zhang N, Ma J, et al
    Effect of tumor microenvironment in pancreatic cancer on the loss of beta-cell mass: implications for type 3c diabetes.
    J Gastroenterol. 2025 Jan 6. doi: 10.1007/s00535-024-02204.
    PubMed     Abstract available
    
    
    December 2024
38. DEVASAHAYAM AROKIA BALAYA R, Sen P, Grant CW, Zenka R, et al
    An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum.
    J Gastroenterol. 2024 Dec 12. doi: 10.1007/s00535-024-02197.
    PubMed     Abstract available
    
    
    
39. KUGIYAMA N, Nagaoka K, Yamada R, Watanabe T, et al
    Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion.
    J Gastroenterol. 2024 Dec 11. doi: 10.1007/s00535-024-02195.
    PubMed     Abstract available
    
    
    
40. NOTOYA G, Kishikawa T, Yasugi K, Iwata T, et al
    WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway.
    J Gastroenterol. 2024 Dec 10. doi: 10.1007/s00535-024-02192.
    PubMed     Abstract available
    
    
    November 2024
41. IMAOKA H, Ikeda M, Kobayashi S, Ohba A, et al
    Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
    J Gastroenterol. 2024 Nov 30. doi: 10.1007/s00535-024-02186.
    PubMed     Abstract available
    
    
    
42. ISHIGAKI K, Tokito Y, Takahara N, Nishio H, et al
    Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database.
    J Gastroenterol. 2024 Nov 21. doi: 10.1007/s00535-024-02173.
    PubMed     Abstract available
    
    
    September 2024
43. MIKI M, Masuda A, Takenaka M, Shiomi H, et al
    Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 16. doi: 10.1007/s00535-024-02149.
    PubMed     Abstract available
    
    
    August 2024
44. WANG P, Huang B, Liu Y, Tan X, et al
    Corynoline protects chronic pancreatitis via binding to PSMA2 and alleviating pancreatic fibrosis.
    J Gastroenterol. 2024 Aug 15. doi: 10.1007/s00535-024-02145.
    PubMed     Abstract available
    
    
    June 2024
45. HIDAKA Y, Tanoue S, Ayukawa T, Takumi K, et al
    Impact of pancreatic ductal occlusion on postoperative outcomes in pancreatic head cancer patients undergoing neoadjuvant therapy.
    J Gastroenterol. 2024 Jun 20. doi: 10.1007/s00535-024-02125.
    PubMed     Abstract available
    
    
    
46. MINAGA K, Otsuka Y, Watanabe T
    High-mobility group box 1: friend or foe in pancreatitis.
    J Gastroenterol. 2024 Jun 17. doi: 10.1007/s00535-024-02123.
    PubMed    
    
    
    
47. ZHAO LJ, Chen P, Huang L, He WQ, et al
    Heparan sulfate acts as an activator of the NLRP3 inflammasome promoting inflammatory response in the development of acute pancreatitis.
    J Gastroenterol. 2024 Jun 12. doi: 10.1007/s00535-024-02127.
    PubMed     Abstract available
    
    
    May 2024
48. HOKKOKU D, Sasaki K, Kobayashi S, Shimbo T, et al
    High-mobility group box 1 fragment ameliorates chronic pancreatitis induced by caerulein in mice.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02112.
    PubMed     Abstract available
    
    
    April 2024
49. MATSUMOTO K, Fujimori N, Ichihara K, Takeno A, et al
    Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.
    J Gastroenterol. 2024 Apr 29. doi: 10.1007/s00535-024-02103.
    PubMed     Abstract available
    
    
    February 2024
50. NAGAO K, Sakai A, Tsumura H, Iemoto T, et al
    Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
    J Gastroenterol. 2024 Feb 29. doi: 10.1007/s00535-024-02083.
    PubMed     Abstract available
    
    
    January 2024
51. KASHIRO A, Kobayashi M, Oh T, Miyamoto M, et al
    Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
    J Gastroenterol. 2024 Jan 23. doi: 10.1007/s00535-023-02072.
    PubMed     Abstract available
    
    
    
52. ABE S, Masuda A, Matsumoto T, Inoue J, et al
    Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2024 Jan 20. doi: 10.1007/s00535-023-02069.
    PubMed     Abstract available
    
    
    November 2023
53. SAKAKIDA T, Ishikawa T, Doi T, Morita R, et al
    Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    J Gastroenterol. 2023 Nov 25. doi: 10.1007/s00535-023-02058.
    PubMed     Abstract available
    
    
    
54. TAKEUCHI C, Sato J, Yamamichi N, Kageyama-Yahara N, et al
    Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiation.
    J Gastroenterol. 2023 Nov 14. doi: 10.1007/s00535-023-02055.
    PubMed     Abstract available
    
    
    September 2023
55. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    PubMed     Abstract available
    
    
    
56. OKUSAKA T, Saiura A, Shimada K, Ikeda M, et al
    Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort.
    J Gastroenterol. 2023 Sep 7. doi: 10.1007/s00535-023-02033.
    PubMed     Abstract available
    
    
    August 2023
57. FISCHMAN M, Elias A, Klein A, Cohen Y, et al
    The association between phosphate level at admission and early mortality in acute pancreatitis.
    J Gastroenterol. 2023 Aug 18. doi: 10.1007/s00535-023-02034.
    PubMed     Abstract available
    
    
    July 2023
58. OYAMA H, Hamada T, Nakai Y, Tanaka M, et al
    Clinical trajectory of intraductal papillary mucinous neoplasms progressing to pancreatic carcinomas during long-term surveillance: a prospective series of 100 carcinoma cases.
    J Gastroenterol. 2023 Jul 29. doi: 10.1007/s00535-023-02028.
    PubMed     Abstract available
    
    
    
59. ASHINA S, Masuda A, Yamakawa K, Hamada T, et al
    A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2023 Jul 21. doi: 10.1007/s00535-023-02020.
    PubMed     Abstract available
    
    
    June 2023
60. TOMIMARU Y, Eguchi H, Shimomura Y, Kitamura T, et al
    Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
    J Gastroenterol. 2023 Jun 17. doi: 10.1007/s00535-023-01988.
    PubMed     Abstract available
    
    
    May 2023
61. KAWASAKI Y, Hijioka S, Nagashio Y, Maruki Y, et al
    Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation.
    J Gastroenterol. 2023 May 8. doi: 10.1007/s00535-023-01995.
    PubMed     Abstract available
    
    
    April 2023
62. SAKAI A, Masuda A, Kodama Y
    Does early intervention for infected pancreatic necrosis lead to better clinical outcomes compared to delayed intervention?
    J Gastroenterol. 2023 Apr 30. doi: 10.1007/s00535-023-01994.
    PubMed    
    
    
    
63. MURAKAMI M, Fujimori N, Nakata K, Nakamura M, et al
    Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
    J Gastroenterol. 2023 Apr 26. doi: 10.1007/s00535-023-01987.
    PubMed     Abstract available
    
    
    
64. SAKAKIDA T, Ishikawa T, Doi T, Morita R, et al
    Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
    J Gastroenterol. 2023 Apr 7. doi: 10.1007/s00535-023-01986.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Pancreatitis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum